At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TPST Tempest Therapeutics Inc.
Not Yet Opened 11-25 16:00:00 EST
0.9151
+0.0096
+1.06%
盘后0.9300
+0.0149+1.63%
19:57 EST
High0.9780
Low0.9050
Vol1.14M
Open0.9050
D1 Closing0.9055
Amplitude8.06%
Mkt Cap39.94M
Tradable Cap19.68M
Total Shares43.64M
T/O1.06M
T/O Rate5.30%
Tradable Shares21.50M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co.
BRIEF-Tempest Receives FDA Study May Proceed For Pivotal Phase 3 Trial Of Amezalpat Combination Therapy For The Treatment Of First-Line Hepatocellular Carcinoma
BRIEF-Tempest Announces Agreement With Roche To Support Advancement Of Amezalpat Combination Therapy Into First-Line Hepatocellular Carcinoma Pivotal Trial
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.